Most people, who were familiar with the volumes of scientific literature that demonstrates both the safety and efficacy of ephedra, have been puzzled why the FDA took the position to ban this highly effective diet aid. In fact, the FDA’s rationale was so flawed that most could not even comprehend it. The FDA’s stance is a follows: 1. ephedra and pseudoephedrine, as OTC drugs, are safe and effective for their intended uses – asthma and as a decongestant. Both have been deemed safe for over 50 years and have had trillions of does sold. 2. Ephedra, as a weight loss aid, is unsafe and cannot be used at any dosage. The FDA says the risks outweigh the rewards in regard to ephedrine alkaloids. How can the same compound be safe, as a drug, and allowed to be sold, and the same compound, as a dietary supplement, be banned? I’ll tell you why the pharmaceutical giants pull the FDA’s strings like a puppet. No other explanation makes sense. This warped, two faced rationale and the FDA’s subsequent actions to enforce its misaligned agenda demonstrates that the FDA’s believes it oversees a public lacking in the intelligence that it operates in complete autonomy from the authority of the Federal Judiciary, and that the separation of powers doctrine of the U.S. Constitution is a fantasy.
Although it was clear to me that the FDA was serving, first and foremost, the needs of the pharmaceutical industry over those of the American public, it wasn’t until recently that the FDA’s special agenda was revealed. I thought maybe the FDA would attempt to make an ephedra plus caffeine synthetic drug combination and market it as an OTC drug. Nothing else made any sense, until the recent announcement of the launch of Alli by Glaxo Smith Kline (Glaxo). What is Alli you may? Alli is an OTC, reduced dose version of Xenical, being launched without a prescription. Roche and Glaxo have partnered to promote the weight loss medication Xenical in the United States. They began talks a few years back about a partnership to much an OTC version of Xenical, and they finalized an agreement in July 2004 for $100 million in which Glaxo acquired the nonprescription marketing rights from Roche,. So, while many in the dietary supplement industy and consuming public may have believed that he FDA was acting out of concern for the safety of Americans by banning ephedra, the real truth was that it was creating an unfair playing field for Alli to enter the marketplace. Glaxo is know for its stable of OTC products, susch as Nicorette, NicoDerm CQ, Abreve, Aquafresh, Sensodyne, and Turns, to name a few. Glaxo’s OTC sales force is one of the strongest in the industry, which will help Alli be competitive in a challenging market. Orlistat is the main ingredient in Alli blocks fat absorption from the food we eat.